Oncology stories
T-cell receptor therapy: A new era for cell therapy in cancer treatment
What science can doUnveiling the Unseen: Uterine Cancer Demands Our Attention
Article
Oncology
We are leading a revolution to transform cancer care
Use a maximum of two downloads here
Home / Our therapy areas / Oncology
We are leading a revolution in oncology with the goal to transform outcomes and increase the chance of cures, following the science to understand cancer and all its complexities to discover, develop and deliver life-changing medicines to patients.
Revolutionising cancer care
We have a bold ambition to eliminate cancer as a cause of death. We are following the science with the aim to deliver innovative medcines across multiple scientific platfroms and pionerring new technologies to screen and diagnose cancer earlier, help to personalise treatment and otimise the care experience for all patients.
We have a vision where cancer can be outsmarted and, in some cases, even cured. We are focusing our efforts on key tumour areas including lung, breast, gastrointestinal, gynaecological, genitourinary and haematology and developing a broad portfolio of personalised treatments that target different subtypes across all stages of disease.
Innovation alone won’t solve cancer – it takes extraordinary people working toward the same goal to achieve this collective purpose. Recognising this, we are accelerating our vision to transform care through partnerships across the healthcare ecosystem that improve access and delivery to improve patient care
[#Our-tumour-focus-areas]
Our tumour areas of focus
Our scientific approach is anchored in the ambition to address unmet patient needs to research and develop next-wave therapies with the greatest potential for patient impact.
[#Our-scientific-platforms]
Our scientific platforms
Across our intentionally designed portfolio, we are harnessing a breadth of scientific platforms to attack cancer from multiple angles. We know that real potential is in the combination of treatments, and the breadth and depth of our portfolio allows us to trial many of these platforms in combinations with the aim to achieve a more durable, deeper response as we strive towards increasing the chance of cures.
Each platform is designed to leverage emerging technologies that deepen biological understanding and help to personalise treatment with the ambition to bring more patients the benefits of innovation. Together, they form the foundation of our strategy to transform cancer care.
[#Oncology-stories]
[#Our-people]
Our people
We are building one of the fastest-growing, highest-performing oncology organisations in the industry — empowering passionate, dedicated people who follow the science, put patients first and work together to deliver life-changing outcomes for patients.
We foster an inclusive and entrepreneurial culture where diversity drives innovation and progress, and where every voice is encouraged to speak up and drive change. Together, we are inspiring and supporting the next-generation of scientists, engineers and healthcare professionals to transform the patient experience in oncology.
The Oncology team is led by:
Please add hero Split Feature Tiles here
Please add non-hero Split Feature Tiles here
[#Join-our-team]
Join our team
Join our team and help us redefine cancer care. Be among colleagues who are driven by our passion, our people and a culture of innovation. We value courage, curiosity, collaboration and a passion for learning. We embrace disruptive thinking where failure is an opportunity to learn – having the freedom to take risks without fear of failure.
[#Our-medicines]
Our medicines
We cannot provide detailed information about our prescription medicines on this website, in compliance with regulations. Our medicines are approved in individual countries for specific uses and the information we provide for patients is governed by local regulations. In some cases, healthcare professionals and patients can visit local AstraZeneca websites to find out more about our medicines. Please note that in some countries we are not allowed to provide very much, or sometimes any, information on our prescription medicines so you should seek alternative trustworthy sources. Always ask a healthcare professional for advice about medicines.
[#Our-pipeline]
Our pipeline for Oncology
We aim to revolutionise cancer care through our portfolio, our pipeline and our people. We follow the science, wherever it takes us, in pursuit of the medicines that improve patient outcomes. Through this relentless quest for innovation, we have created one of the most diverse portfolios and pipelines in the industry —and help to deliver on our strategy to treat early with curative intent while continuing to address metastatic and resistant disease.
We are balancing focus on our industry-leading pipeline with the active life-cycle management of our existing medicines; using the power of novel combinations with the aim to drive deeper, more durable responses and transform outcomes for more patients.
Phase III/LCM Projects: refers to assets that are pivotal in Phase II/III or have been submitted for regulatory approval and may include assets that are launched in one or more major markets (removed when launched in all applicable major markets).
Veeva ID: Z4-79847
Date of preparation: March 2026